Answers are grounded in this paper and cite their sources.
// Shabarni Gupta 1, * , Shuvolina Mukherjee 1, * , Parvez Syed 1, 2, * , Narendra Goud Pandala 1 , Saket Choudhary 3, 4 , Vedita Anand Singh 1 , Namrata Singh 1 , Heng Zhu 5 , Sridhar Epari 6 , Santosh B. Noronha 3 , Aliasgar Moiyadi 7 and Sanjeeva Srivastava 1 1 Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India 2 Department of Biochemistry/Biotechnology, University of Turku, Turun yliopisto, Finland 3 Department of Chemical Engineering, Indian Institute of Technology Bombay, Mumbai, India 4 Molecular and Computational Biology, Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA 5 Department of Pharmacology and Molecular Sciences/High-Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA 6 Department of Pathology, Tata Memorial Centre, Mumbai, India 7 Department of Neurosurgery, Tata Memorial Centre, Mumbai, India * These authors have contributed equally to this work Correspondence to: Sanjeeva Srivastava, email: sanjeeva@iitb.ac.in Keywords: meningioma, autoantibody, protein array, brain tumors, HuPort screening Received: July 14, 2016 Accepted: March 11, 2017 Published: April 10, 2017 ABSTRACT Meningiomas are one of the most common tumors of the Central nervous system (CNS). This study aims to identify the autoantibody biomarkers in meningiomas using high-density human proteome arrays (~17,000 full-length recombinant human proteins). Screening of sera from 15 unaffected healthy individuals, 10 individuals with meningioma grade I and 5 with meningioma grade II was performed. This comprehensive proteomics based investigation revealed the dysregulation of 489 and 104 proteins in grades I and II of meningioma, respectively, along with the enrichment of several signalling pathways, which might play a crucial role in the manifestation of the disease. Autoantibody targets like IGHG4, CRYM, EFCAB2, STAT6, HDAC7A and CCNB1 were significantly dysregulated across both the grades. Further, we compared this to the tissue proteome and gene expression profile from GEO database. Previously reported upregulated proteins from meningioma tissue-based proteomics obtained from high-resolution mass spectrometry demonstrated an aggravated autoimmune response, emphasizing the clinical relevance of these targets. Some of these targets like SELENBP1 were tested for their presence in tumor tissue using immunoblotting. In the light of highly invasive diagnostic modalities employed to diagnose CNS tumors like meningioma, these autoantibody markers offer a minimally invasive diagnostic platform which could be pursued further for clinical translation.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: